[Experimental and clinical studies of fortimicin in the field of dermatology].
1. Fortimicin (KW-1070) was found to be similar to amikacin in vitro activity against S. aureus of 27 strains and S. epidermidis of 17 strains isolated in dermatological field. 2. Serum and skin levels of the drug were determined in rats. Mean serum levels (n = 4) were 4.91 mcg/ml at 1/4 hour, 2.40 mcg/ml at 1/2 hour, 2.40 mcg/ml at 1 hour and 0.51 mcg/ml at 2 hours. The corresponding skin levels were 2.15 mcg/g, 2.27 mcg/g, 0.83 mcg/g and 0.19 mcg/g. 3. Seven cases with dermatological infections were treated with fortimicin. No side effects were observed both in subjective and in laboratory findings.
D000368:Aged; D000617:Aminoglycosides / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D051381:Rats; D012867:Skin / Q000378:metabolism; D012874:Skin Diseases, Infectious / Q000188:drug therapy / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C023521:fortimicins